Thermo Fisher Scientific (TMO) versus Thoratec (THOR) Head-To-Head Analysis

Thoratec (NASDAQ: THOR) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Thoratec and Thermo Fisher Scientific, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thoratec 0 0 0 0 N/A
Thermo Fisher Scientific 0 1 14 0 2.93

Thermo Fisher Scientific has a consensus target price of $220.92, suggesting a potential upside of 3.50%.


This table compares Thoratec and Thermo Fisher Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Thoratec 10.29% 8.02% 6.71%
Thermo Fisher Scientific 10.64% 16.01% 7.35%

Earnings & Valuation

This table compares Thoratec and Thermo Fisher Scientific’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Thoratec N/A N/A N/A $0.70 N/A
Thermo Fisher Scientific $20.92 billion 4.10 $2.23 billion $6.11 34.94

Thermo Fisher Scientific has higher revenue and earnings than Thoratec. Thoratec is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.


Thermo Fisher Scientific pays an annual dividend of $0.60 per share and has a dividend yield of 0.3%. Thoratec does not pay a dividend. Thermo Fisher Scientific pays out 9.8% of its earnings in the form of a dividend.

Institutional & Insider Ownership

87.7% of Thermo Fisher Scientific shares are held by institutional investors. 0.5% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Thermo Fisher Scientific beats Thoratec on 9 of the 10 factors compared between the two stocks.

About Thoratec

Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company’s product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables. The Analytical Instruments segment provides a range of instruments, consumables, software and services. The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers controlled temperature technologies products, growth protection and separation products, and water and laboratory products.

Receive News & Ratings for Thoratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thoratec and related companies with's FREE daily email newsletter.

Leave a Reply